MCL1 and Miyoshi myopathy: Developed in 2017 by AstraZeneca, indole-2-carboxylic acids analog AZD5991, is a potent and selective macrocyclic Mcl-1 inhibitor that rapidly activates Caspase proteins, which leads to apoptosis in MM cell lines (GI50 = 10 nM) (Hird and et al., 2017; Tron et al., 2018).